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Impact of Triglyceride Levels Beyond
Low-Density Lipoprotein Cholesterol After Acute
Coronary Syndrome in the PROVE IT-TIMI 22 Trial
Michael Miller, MD, FACC,* Christopher P. Cannon, MD, FACC,† Sabina A. Murphy, MPH,†
Jie Qin, MS,† Kausik K. Ray, MD, MRCP,‡ Eugene Braunwald, MD, MACC,†
for the PROVE IT-TIMI 22 Investigators
Baltimore, Maryland; Boston, Massachusetts; and Cambridge, United Kingdom
Objectives The purpose of this study was to assess the impact of on-treatment triglycerides (TG) on coronary heart disease
(CHD) risk after an acute coronary syndrome (ACS).
Background The PROVE IT-TIMI (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial In-
farction) 22 trial demonstrated that low-density lipoprotein cholesterol (LDL-C) 70 mg/dl was associated with
greater CHD event reduction than LDL-C 100 mg/dl after ACS. However, the impact of low on-treatment TG on
CHD risk beyond LDL-C 70 mg/dl has not been explored.
Methods The PROVE IT-TIMI 22 trial evaluated 4,162 patients hospitalized for ACS and randomized to atorvastatin 80 mg
or pravastatin 40 mg daily. The relationship between on-treatment levels of TG and LDL-C and the composite
end point of death, myocardial infarction (MI), and recurrent ACS were assessed 30 days after initial presentation.
Results Low on-treatment TG (150 mg/dl) was associated with reduced CHD risk compared with higher TG in univari-
ate analysis (hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.62 to 0.87; p  0.001) and in adjusted anal-
ysis (HR 0.80, 95% CI 0.66 to 0.97; p  0.025). For each 10-mg/dl decrement in on-treatment TG, the incidence
of death, MI, and recurrent ACS was lower by 1.6% or 1.4% after adjustment for LDL-C or non–high-density
lipoprotein cholesterol and other covariates (p  0.001 and p  0.01, respectively). Lower CHD risk was also
observed with TG 150 mg/dl and LDL-C 70 mg/dl (HR 0.72, 95% CI 0.54 to 0.94; p  0.017) or low on-
treatment TG, LDL-C, and C-reactive protein (2 mg/l) (HR 0.59, 95% CI 0.41 to 0.83; p  0.002) compared
with higher levels of each variable in adjusted analysis.
Conclusions On-treatment TG 150 mg/dl was independently associated with a lower risk of recurrent CHD events, lending
support to the concept that achieving low TG may be an additional consideration beyond low LDL-C in patients
after ACS. (The PROVE IT-TIMI 22 trial; NCT00382460) (J Am Coll Cardiol 2008;51:724–30) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.038a
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apidemiologic surveys have observed that elevated levels of
otal cholesterol and low-density lipoprotein cholesterol
LDL-C) are associated with increased risk of coronary
eart disease (CHD) (1), and therapeutic strategies that lead
o a statistically significant reduction in LDL-C lower CHD
vent rates (2). The magnitude of CHD risk reduction as a
onsequence of LDL-C lowering often ranges between 25%
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2nd 35% (3). One potential impediment limiting further
eduction in CHD events despite low on-treatment LDL-C is
esidual elevation in serum triglyceride (TG) levels (4). His-
orically, elevated TG has predicted CHD events in univariate
nalysis, only to weaken after adjustment for other covariates,
ncluding plasma glucose and high-density lipoprotein choles-
erol (HDL-C), to which it is strongly and inversely correlated
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February 19, 2008:724–30 Impact of Triglycerides After ACS5). Yet, even after adjustment for HDL-C, detailed evaluation
f population-based prospective studies has disclosed an inde-
endent effect of TG on CHD events (6). Coupled with the
nowledge that combined hyperlipidemia (i.e., elevated
DL-C and TG) promotes CHD to a significantly greater
xtent than either high LDL-C or TG alone (7), the
resent analysis was undertaken to test the hypothesis that
ow on-treatment levels of TG when added to low LDL-C
ould be superior to low LDL-C alone in reducing subse-
uent CHD events after an acute coronary syndrome
ACS).
ethods
tudy population and protocol. The study population orig-
nated from the PROVE IT-TIMI (Pravastatin or Atorvasta-
in Evaluation and Infection Therapy-Thrombolysis In Myo-
ardial Infarction) 22 trial, a study prospectively designed to
ompare the effect of intensive versus standard therapy to
educe LDL-C, as previously reported (8,9). Briefly, 4,162
en and women hospitalized for ACS with total cholesterol
240 mg/dl, or 200 mg/dl if receiving lipid-lowering ther-
py, were randomly assigned to receive intensive therapy
atorvastatin 80 mg daily) or standard therapy (pravastatin 40
g daily) for a mean follow-up period of 2 years. In addition,
atifloxacin versus placebo was tested concomitantly in a
actorial design. Total cholesterol, TG, and HDL-C were
easured using an enzymatic colorimetric assay (Roche Mod-
lar system, Roche Diagnostics, Indianapolis, Indiana) after
he recommended 12-h overnight fast (10). The LDL-C was
stimated using the formula: total cholesterol  (TG/5 
DL-C) (11), or directly measured if TG exceeded 400
g/dl. Lipid and lipoprotein levels were obtained at base-
ine, 1, 4, 8, 16, and 24 months, and the final visit. The
aseline Characteristics by TG Quintile at 30 Days After an ACS
Table 1 Baseline Characteristics by TG Quintile at 30 Days Aft
Characteristic 1 (n  763) 2 (n  753)
General
Mean age, yrs 59.7 59.2
Men, % 81.9 78.9
Coronary risk factors, %
Current smoker 30.0 34.0
Hypertension 46.7 45.3
Obesity (BMI 30 kg/m2) 28.4 34.8
Diabetes 13.8 16.1
Prior ACS 22.4 23.5
Prior statin use 20.3 21.9
Peripheral vascular disease 4.6 6.1
Lipids and lipoproteins, median (IQR)
TG, mg/dl 69 (59–77) 97 (90–102)
Total cholesterol, mg/dl 120 (100–146) 130 (112–153)
LDL-C, mg/dl 63 (47–82) 68 (53–88)
HDL-C, mg/dl 42 (36–50) 41 (35–47)
High-sensitivity CRP, mg/l 1.41 (0.66–3.31) 1.90 (0.87–4.26)CS  acute coronary syndrome; BMI  body mass index; CRP  C-reactive protein; HDL-C  high-dens
G  triglycerides.omposite end point of death,
yocardial infarction (MI), or
ecurrent ACS was used as pre-
iously outlined (12).
tatistical analysis. Kaplan-
eier event rates for the com-
osite end point of interest were
etermined during follow-up (at
years) after censoring patients
ith events within 30 days of the
nitial ACS event. Hazard ratios
HRs) and associated 95% confi-
ence intervals (CIs) were calcu-
ated using selected cut-points as
eferents. Cut-points were de-
ived from the National Cholesterol Education Program
dult Treatment Panel III guidelines (13,14) and included:
DL-C 70 mg/dl, the optional target goal in ACS
atients; TG150 mg/dl, the normal designate also used in
he metabolic syndrome classification; and HDL-C 40
g/dl in men and 50 mg/dl women, as similarly classified
14). In addition, other selected cut-points for TG (100 and
00 mg/dl) and non–HDL-C (100 and 130 mg/dl) were
valuated (13–15). The impact of TG 150 mg/dl with
chieved dual parameters of low LDL-C (70 mg/dl) and
-reactive protein (CRP;2 mg/l) (16) on recurrent CHD
vents was also examined. A Cox proportional hazards
odel included clinically important variables (e.g., age,
ender, smoking, hypertension, obesity, diabetes), potential
onfounders or effect modifiers (e.g., low HDL-C, periph-
ral vascular disease, prior statin therapy, prior ACS), and
ntervention (atorvastatin 80 mg/day vs. pravastatin 40
g/day) to estimate the effect of on-treatment LDL-C and
ACS
TG Quintile
Total (n  3,718)(n  737) 4 (n  732) 5 (n  733)
Mean
58.8 57.5 55.3 58.1
76.0 74.0 82.0 78.6
33.7 41.3 42.4 36.2
51.7 51.8 51.6 49.4
39.2 43.8 51.3 39.4
16.4 19.1 20.6 17.2
28.1 28.3 34.8 27.4
26.5 27.1 31.8 25.5
5.4 5.5 6.6 5.6
3 (116–130) 162 (150–177) 254 (218–317)
8 (118–160) 152 (127–178) 170 (147–193)
3 (54–92) 78.5 (57–102) 81 (59–101)
0 (34–47) 38 (32–45) 35 (30–42)
3 (0.95–4.36) 2.15 (1.02–4.43) 2.36 (1.14–4.43)
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CHD  coronary heart
disease
CRP  C-reactive protein
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
MI  myocardial infarction
TG  triglycerideser an
3
12
13
7
4
1.9ity lipoprotein cholesterol; IQR  interquartile range; LDL-C  low-density lipoprotein cholesterol;
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Impact of Triglycerides After ACS February 19, 2008:724–30G in the adjusted analysis. The proportional hazards
ssumption was evaluated for each model. Additionally, risk
stimates were used to determine the relative decrease in
azard associated with each on-treatment change of 10
g/dl for lipids and lipoproteins. We also assessed the
elative change in hazard for each 10% lowering of TG that
ccurred between baseline and the first month of therapy in
tatin-naïve patients. All analyses were conducted on data
hrough 2 years of follow-up. Statistical analysis was per-
ormed using Stata/SE version 9.2 (StataCorp, College
tation, Texas).
esults
tudy population and baseline characteristics. Of the
,162 patients initially enrolled in the PROVE IT-TIMI 22
rial, the present analysis focuses on the incidence of death,
I, or rehospitalization for ACS beginning after an event-
ensored interval of 30 days (n  3,718), with follow-up
hrough 2 years. Baseline characteristics (Table 1) identified
predominantly male cohort (79%), with a relatively high
ercentage of smokers (36%), hypertension (49%), and
besity (39%). At increasing TG quintiles, there were
orresponding increases in LDL-C and decreases in
DL-C. A scatterplot analysis demonstrated a positive
orrelation between TG and LDL-C (Spearman rho 
.20; p  0.0001) and inverse correlation between TG and
DL-C (Spearman rho  0.24; p  0.0001).
ontinuous risk estimates for LDL-C, TG, and HDL-C.
Cox proportional hazards model was used to evaluate
DL-C, non–HDL-C, TG, HDL-C, and CRP as contin-
ous variables (Table 2). The univariate relative decrease in
azard associated with each 10-mg/dl reduction in LDL-C
nd non–HDL-C was 4.0% and 4.8%, respectively (p 
.01), whereas each 10 mg/dl decrement in TG was
ssociated with a 1.8% reduction in risk (p  0.001).
owever, only TG remained statistically significantly asso-
isk Estimates* for Death, MI, and Recurrent ACS0 Days After ACS Using Selected Continuousariables
Table 2
Risk Estimates* for Death, MI, and Recurrent ACS
30 Days After ACS Using Selected Continuous
Variables
Variable
Unadjusted Risk
Estimates (95% CI)
Adjusted Risk
Estimates (95% CI)
p Value,
Adjusted
Analysis
LDL-C 1.040 (1.009–1.068) 1.016 (0.984–1.055)† 0.302
Non–HDL-C 1.048 (1.024–1.073) 1.020 (0.986–1.055)‡ 0.252
Triglycerides 1.018 (1.011–1.026) 1.016 (1.007–1.025)† 0.001
1.014 (1.003–1.025)‡ 0.010
HDL-C 1.034 (0.959–1.114) 1.038 (0.952–1.132)† 0.401
1.031 (0.944–1.126)‡ 0.497
CRP 1.008 (1.002–1.014) 1.004 (0.998–1.011)‡ 0.195
Relative decrease in hazard for each 10-mg/dl change in LDL-C, TG, or HDL-C or 1-mg/l change in
RP. †Model includes continuous LDL-C, continuous TG, continuous HDL-C, age, gender, smoking,
ypertension, obesity, diabetes, prior statin therapy, prior ACS, peripheral vascular disease, and
reatment effect. ‡Model includes continuous non–HDL-C, continuous TG, continuous HDL-C, CRP,
ge, gender, smoking, hypertension, obesity, diabetes, prior statin therapy, prior ACS, peripheral
ascular disease, and treatment effect.
CI  confidence interval; MI  myocardial infarction; other abbreviations as in Table 1.iated with death, MI, and recurrent ACS after covariatedjustment that included LDL-C (p  0.001) or non–
DL-C (p  0.010).
ffect of lowering TG levels on the composite end
oint. A Cox proportional model was also used to assess
he effect of TG lowering on the composite end point in
tatin-naïve subjects (n  2,587). For each 10% lowering of
G that was attained during the first month of therapy,
here was a 2.7% (p  0.003) reduced incidence of subse-
uent events in unadjusted analysis and a 2.3% (p  0.035)
ower incidence after adjustment for other covariates includ-
ng high LDL-C (70 mg/dl) and low HDL-C (40
g/dl in men and 50 mg/dl and women).
Figure 1 Kaplan-Meier Curves
Estimates of death, myocardial infarction, and recurrent acute coronary syndrome
between 30 days and 2 years of follow-up based on (A) achieved low-density
lipoprotein cholesterol (LDL-C) 70 mg/dl and (B) triglycerides (TG) 150 mg/dl.
The 95% confidence intervals are in parentheses. HR  hazard ratio.
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February 19, 2008:724–30 Impact of Triglycerides After ACSn-treatment effects using various cut-points of
DL-C, TG, and non–HDL-C. The subsequent series of
nalyses focused on events based on National Cholesterol
ducation Program cut-points for LDL-C and TG. At 30
ays, 34.6% of patients had TG 150 mg/dl. Between 30
ays and the 2-year follow-up, significantly fewer events
ccurred among patients with LDL-C 70 mg/dl (13.0%)
han with LDL-C 70 mg/dl (16.2%) (HR 0.81, 95% CI
.68 to 0.96; p  0.015) (Fig. 1A). Similarly, fewer events
ccurred with TG 150 mg/dl (13.2%) than with TG
150 mg/dl (17.6%) (HR 0.73, 95% CI 0.62 to 0.87; p 
.001) in univariate analysis (Fig. 1B) and after adjustment
or age, gender, high LDL-C, low HDL-C, smoking,
ypertension, obesity, diabetes, prior statin therapy, prior
CS, peripheral vascular disease, and treatment effect (HR
.80, 95% CI 0.66 to 0.97; p  0.025). A Cox proportional
odel further examined the relationship between achieved
DL-C and TG at 30 days and risk of recurrent events.
ompared with LDL-C 70 mg/dl and TG 150 mg/dl
referent), lower CHD risk was observed with low on-
Figure 2 Risk of Recurrent Events Using
Selected Cut-Points of LDL-C and TG
Event rate and adjusted hazard of death, myocardial infarction (MI), and recur-
rent acute coronary syndrome (ACS) between 30 days and 2 years of follow-up
with achieved LDL-C and TG based on the designated cut-points of 70 mg/dl
and 150 mg/dl, respectively. The referent (Ref) group is LDL-C 70 mg/dl and
TG 150 mg/dl. This model is adjusted for age, gender, low HDL-C, smoking,
hypertension, obesity, diabetes, prior statin therapy, prior ACS, peripheral vas-
cular disease, and treatment effect. The 95% confidence intervals are located
below the HRs. Abbreviations as in Figure 1.
isk of Death, MI, or Recurrent ACS With LDL-C <70 mg/dlnd Selected On-Treatment TG or Non–HDL-C Cut-Points 30 Days A
Table 3 Risk of Death, MI, or Recurrent ACS With LDL-C <70and Selected On-Treatment TG or Non–HDL-C Cut-Point
LDL-C <70 mg/dl
 Variable Patients, n Rate, %
Un
TG 200 mg/dl 603 20.3
TG 200 mg/dl 2,796 13.5
TG 100 mg/dl 2,259 15.4
TG 100 mg/dl 1,140 13.4
Non–HDL-C 130 mg/dl 741 17.9
Non–HDL-C 130 mg/dl 2,652 13.9
Non–HDL-C 100 mg/dl 1,676 16.5
Non–HDL-C 100 mg/dl 1,718 13.1
Adjusted for age, gender, low HDL-C, smoking, hypertension, obesity, diabetes, prior statin therap
G or non–HDL-C.
Abbreviations as in Tables 1 and 2.reatment TG (150 mg/dl) and LDL-C (70 mg/dl)
HR 0.72, 95% CI 0.54 to 0.94; p  0.017), with a graded
esponse among patients with LDL-C 70 mg/dl and TG
150 mg/dl (HR 0.85, 95% CI 0.67 to 1.08; p  0.180) in
djusted analysis (Fig. 2). Low HDL-C was not associated
ith increased risk of CHD events after covariate adjust-
ent (HR 1.01, 95% CI 0.84 to 1.22; p 0.911). Similarly,
valuation of LDL-C70 mg/dl with varying cut-points of
G (100 and 200 mg/dl) and non–HDL-C (100 and 130
g/dl), identified a statistically significantly lower risk with
G 200 mg/dl (HR 0.60, 95% CI 0.45 to 0.81; p 
.001) and a nonsignificant trend with TG 100 mg/dl
HR 0.82, 95% CI 0.61 to 1.10; p  0.189), non–HDL-C
130 mg/dl (HR 0.79, 95% CI 0.61 to 1.02; p  0.067),
nd non–HDL-C 100 mg/dl (HR 0.83, 95% CI 0.66 to
.05; p  0.123) compared with higher levels of LDL-C,
G, or non–HDL-C in adjusted analysis (Table 3).
ttainment of LDL-C <70 mg/dl and TG <150 mg/dl
ith atorvastatin 80 mg/day and pravastatin 40 mg/
ay. The proportion of patients with achieved LDL-C
70 mg/dl or TG 150 mg/dl, the dual parameter
LDL-C 70 mg/dl and TG 150 mg/dl), or the triple
arameter (LDL-C 70 mg/dl, CRP 2 mg/l, and TG
150 mg/dl) at 30 days stratified by treatment arm is shown
n Table 4. Overall, a higher percentage of atorvastatin 80
g/day patients attained any of these parameters than
ravastatin 40 mg/day patients (p  0.0001 for each
omparator). However, even with the more intensive lipid-
owering regimen, only 56.1% of atorvastatin-treated pa-
ients attained LDL-C 70 mg/dl and TG 150 mg/dl,
nd only 35% achieved all 3 parameters.
n-treatment effects of LDL-C <70 mg/dl, CRP <2
g/l, and TG <150 mg/dl. The association between TG
nd recurrent CHD events was further assessed in the
resence of achieved LDL-C 70 mg/dl and CRP 2
g/l, previously noted to be associated with improved
vent-free survival (16). The risk of death, MI, or recurrent
CS after achieving 1, 2, or all 3 parameters (i.e., LDL-C
70 mg/dl, CRP 2 mg/l, and/or TG 150 mg/dl) is
hown in Table 5. Between 30-day and 2-year follow-up,
CS
l
Days After ACS
ed Hazard Ratio
95% CI)
Adjusted Hazard Ratio
(95% CI)*
p Value,
Adjusted Analysis
1.00 0.76 (0.52–1.12) 0.170
(0.53–0.78) 0.60 (0.45–0.81) 0.001
1.00 0.90 (0.71–1.14) 0.368
(0.71–1.03) 0.82 (0.61–1.10) 0.189
1.00 0.83 (0.26–2.63) 0.755
(0.63–0.93) 0.79 (0.61–1.02) 0.067
1.00 1.07 (0.73–1.56) 0.722
(0.66–0.94) 0.83 (0.66–1.05) 0.123
ACS, peripheral vascular disease, and treatment effect compared with higher levels of LDL-C andfter A
mg/d
s 30
adjust
(
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Impact of Triglycerides After ACS February 19, 2008:724–30he risk of the composite end point was 28% lower in the
resence of any 1 parameter (p  0.017), 32% lower with
ny 2 parameters (p  0.007), and 41% lower when all 3
arameters were achieved compared with their absence (p
.002) in an adjusted analysis.
iscussion
n this analysis of the PROVE IT-TIMI 22 trial, the most
oteworthy finding was the reduced risk of CHD with low
n-treatment TG (150 mg/dl) that was independent of
he level of LDL-C. For each 10-mg/dl decline in on-
reatment TG, we observed a 1.6% lower risk of the
omposite end point (p  0.001) after adjustment for
DL-C and other covariates. Moreover, the combination of
ow LDL-C (70 mg/dl) and low TG (150 mg/dl) was
ssociated with the lowest event rates compared with higher
DL-C, higher TG, or both. Our observations on the
elationship between lower event rates with reduced on-
reatment TG are consistent with 2 recent studies. They
nclude a large Chinese prospective study that found TG to
e predictive of CHD mortality, even in the setting of low
otal cholesterol (17), and the Prospective Cardiovascular
ünster study stratified by HDL-C, which identified a
igher CHD risk with high TG (150 mg/dl) in subjects at
ll levels of LDL-C (18). Taken together, aiming for low
n-treatment levels of LDL-C and TG may be particularly
ffective after ACS where residual CHD risk remains
levated despite recent diagnostic and therapeutic advance-
ents (19).
ercentage of TG Reduction and Proportion oftorvastatin- and Pravas atin-Treated Patientstaining Designated Cu -Points fo LDL-C, TG,nd/or CRP 30 Days After ACS
Table 4
Percentage of TG Reduction and Proportion of
Atorvastatin- and Pravastatin-Treated Patients
Attaining Designated Cut-Points for LDL-C, TG,
and/or CRP 30 Days After ACS
Atorvastatin
80 mg
Pravastatin
40 mg
TG reduction
Mean 22.8% 0.7%*
Median 30.3% 8.6%*
LDL-C 70 mg/dl 72.5% 21.6%*
TG 150 mg/dl 74.4% 56.3%*
LDL-C 70 mg/dl, TG 150 mg/dl 56.1% 12.0%*
LDL-C 70 mg/dl, CRP 2 mg/l, TG 150 mg/dl 35.0% 6.6%*
p  0.001 between the treatment groups.
Abbreviations as in Tables 1 and 2.
isk of Death, Myocardial Infarction, or Recurrent ACS by Number
Table 5 Risk of Death, Myocardial Infarction, or Recurrent ACS
Variable Patients, n Rate, %
Unad
No parameters 445 21.1
Any 1 parameter 1,168 15.7 0
Any 2 parameters 1,262 13.7 0
All 3 parameters 757 10.9 0
Parameters are defined as LDL-C70mg/dl, TG150mg/dl, and CRP2mg/l. †Adjusted for a
ascular disease, and treatment effect.
Abbreviations as in Tables 1 and 2.The PROVE IT-TIMI 22 trial (9) and the Heart
rotection Study (20) served as the impetus for the National
holesterol Education Program’s optional recommended
DL-C target of 70 mg/dl (14). Whereas lowering
DL-C to 70 mg/dl has been recommended, the impact
f low on-treatment TG beyond achieved LDL-C 70
g/dl has been less well defined. For example, although TG
evels 150 mg/dl are defined as normal, the National
holesterol Education Program does not recommend TG
owering as a primary target of therapy. Rather, non–
DL-C (e.g., total cholesterol  HDL cholesterol) has
ecome a secondary target when TG levels exceed 200
g/dl (13).
However, several lines of evidence support TG as a
iomarker of CHD risk owing to the role of TG-rich
ipoproteins in atherothrombosis. Following the hydrolysis
f exogenously derived chylomicrons or endogenously se-
reted very-low-density lipoprotein, cholesterol-enriched
emnant by-products enter the subendothelial space. In
ypertriglyceridemic states, remnants accumulate, resulting
n a proinflammatory and oxidative milieu that may enhance
dhesion molecule expression, foam cell formation, and
mooth muscle cell toxicity (21). Indirectly, high levels of
G may also be associated with hypertriglyceridemic HDL
articles, which are thought to be less efficient in reverse
holesterol transport (22,23), as well as an increased pro-
ortion of small, dense LDL particles which may be more
usceptible to oxidative modification (24,25). The fact that
lasma TG correlates with atherogenic remnants (26),
oupled with the excess risk of CHD with combined
levation of LDL-C and TG (27), supports the notion that
ow on-treatment LDL-C and TG may improve CHD risk
eyond low LDL-C alone. The 1.6% reduction in risk
ssociated with each 10-mg/dl decrement in on-treatment
G that is independent of the reduction in risk associated
ith decreases in LDL-C or non–HDL-C is noteworthy
ecause it includes adjustment of other closely aligned TG
ovariates (e.g., diabetes, hypertension, obesity, and
DL-C). Moreover, the 2.3% lower incidence of recurrent
HD events associated with each 10% lower TG concen-
ration (after adjustment for high LDL-C and low
DL-C) raises the possibility that additional reduction in
HD risk may be attained through efforts aimed at lower-
ng both LDL-C and TG compared with lowering LDL-C
rameters Achieved* 30 Days After ACS
umber of Parameters Achieved* 30 Days After ACS
Hazard Ratio
% CI)
Adjusted Hazard Ratio
(95% CI)†
p Value,
Adjusted Analysis
.00 1.00
.56–0.93) 0.72 (0.56–0.94) 0.017
.49–0.83) 0.68 (0.52–0.90) 0.007
.37–0.67) 0.59 (0.41–0.83) 0.002
der, low HDL-C, smoking, hypertension, obesity, diabetes, prior statin therapy, prior ACS, peripheralof Pa
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February 19, 2008:724–30 Impact of Triglycerides After ACSlone. Accordingly, if a combined strategy of low LDL-C
nd low TG proves to be more effective in reducing CHD
vents than intensive LDL-C lowering alone, then addi-
ional strategies might be considered after ACS, including
eplacement of saturated and trans fats with mono- and
olyunsaturated fats (28), especially derivatives such as
mega-3 fatty acids that are cardioprotective and at high
oses possess TG-lowering properties (29,30), or the addi-
ion of niacin- or fibrate-based therapy, which is currently
nder investigation for CHD event rate reduction beyond
DL-C lowering (31,32).
In the present analysis, lower HDL-C levels were not
ssociated with an increased risk of death, MI, or recurrent
CS when used as either a categoric or continuous variable.
lthough placebo-assigned patients with low HDL-C have
raditionally had the highest event rates (33), this associa-
ion may have been partly minimized in the PROVE
T-TIMI 22 trial, because all patients received statin
herapy that may have attenuated the excess risk associated
ith low HDL-C (34). The basis for this effect may reflect,
n part, statin-mediated reduction in atherogenic lipopro-
eins and remnants (35) as well as the potential decrease in
ellular adhesion molecule expression (36) that may be
p-regulated in patients with low HDL-C (37). Previously,
he combination of LDL-C 70 mg/dl and CRP 2 mg/l
as shown to be associated with statistically significant
eductions in recurrent MI or vascular death compared with
igher levels of LDL-C and CRP (38). Moreover, in the
ROVE IT-TIMI 22 trial, high CRP was also found to be
ssociated with each of the factors comprising the metabolic
yndrome (39). In the present study, there was a 41% lower
isk of CHD events between 30 days after ACS and the
-year follow-up with attainment of LDL-C 70 mg/dl,
RP 2 mg/l, and TG 150 mg/dl compared with higher
evels in all 3 parameters after adjustment for other covari-
tes. Mechanistically, if elevated TG represents in part a
rothrombotic state (40,41), then low on-treatment levels of
DL-C, CRP, and TG may be a consideration in ACS
atients, owing to the intimate linkage between lipids,
nflammation, and thrombosis (42). This may justify con-
ideration of other therapies (29–31,43–46) if future clinical
rials demonstrate clinical benefit beyond LDL-C lowering.
tudy limitations. There are several important limitations
ssociated with the present study. First, it was not designed
priori to address whether combined low on-treatment
DL-C and TG was superior to low on-treatment LDL-C
lone. Second, greater intraindividual variability has been
eported for TG than for LDL-C (47). Nevertheless,
lthough standard statistical methods were used to account
or known variability, a recent evaluation of repeat TG
easurements over a 4- or 12-year period (n  2,312)
dentified long-term stability of TG that was similar to
lood pressure and other lipid measurements (6). Third, the
esults of the present study are not generalizable to
onstatin-based therapies. Finally, although the study as-
essed outcomes of patients who were observed to have TG150 mg/dl at different levels of LDL-C, it remains to be
onfirmed in randomized trials whether, and to what extent,
argeting a lower on-treatment TG (15) may provide
dditional clinical benefit.
onclusions
mong patients receiving statin therapy after ACS, on-
reatment TG 150 mg/dl was associated with a lower risk
f recurrent CHD events independently of the level of
DL-C. These data lend support to the concept that
chieving both a low LDL-C and a low TG may be
mportant therapeutic parameters in patients following
CS.
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